Loading...
Le laboratoire AGIR s’intéresse à la conception, la synthèse et l'évaluation biologique de nouveaux anti-infectieux capables de combattre les phénomènes de résistance. En effet, après avoir révolutionné la médecine moderne et considérablement augmenté l’espérance de vie dans les pays développés, l’antibiothérapie traverse en ce XXIème siècle une crise mondiale du fait de l’apparition de multiples résistances bactériennes. La lutte contre les phénomènes de résistance constitue donc l'un des enjeux majeurs de l'antibiothérapie moderne.
Dernières publications
-
Steffi Rocchi, Emeline Scherer, P. Lewis White, Audrey Guitton, Alexandre Alanio, et al.. Interlaboratory assays from the fungal PCR Initiative and the Modimucor Study Group to improve qPCR detection of Mucorales DNA in serum: one more step toward standardization. Journal of Clinical Microbiology, In press, pp.e0152524. ⟨10.1128/jcm.01525-24⟩. ⟨hal-04862485⟩
-
Sandra Albenque-Rubio, Jean Guillon, Patrice Agnamey, Céline Damiani, Solène Savrimoutou, et al.. Design, Synthesis, and In Vitro Antimalarial Evaluation of New 1,3,5-Tris[(4-(Substituted-Aminomethyl)Phenoxy)Methyl]Benzenes. Drugs and Drug Candidates, 2024, 3 (3), pp.615-637. ⟨10.3390/ddc3030035⟩. ⟨hal-04701065⟩
-
Marine Bentz, Louison Collet, Virginie Morel, Véronique Descamps, Emmanuelle Blanchard, et al.. The Conserved YPX3L Motif in the BK Polyomavirus VP1 Protein Is Important for Viral Particle Assembly but Not for Its Secretion into Extracellular Vesicles. Viruses, 2024, 16 (7), pp.1124. ⟨10.3390/v16071124⟩. ⟨hal-04653798⟩
-
Lucie Barateau, Sébastien Baillieul, Claire Andrejak, Émilie Bequignon, Pierre Boutouyrie, et al.. Guidelines for the assessment and management of residual sleepiness in obstructive apnea-hypopnea syndrome. Endorsed by the French Sleep Research and Medicine Society (SFRMS) and the French Speaking Society of Respiratory Diseases (SPLF). Respiratory Medicine and Research, 2024, pp.101105. ⟨10.1016/j.resmer.2024.101105⟩. ⟨hal-04543619⟩
-
Simplice Dzamitika, Françoise Le Boulaire, Catherine Coignard, Claire Vincent, Jean-Christophe Plantier, et al.. Performance Evaluation of the Access anti-HBc Total Assay on the DxI 9000 Access Immunoassay Analyzer. Diagnostic Microbiology and Infectious Disease, 2024, 110 (1), pp.116303. ⟨10.1016/j.diagmicrobio.2024.116303⟩. ⟨hal-04560988⟩
-
Vida Terzić, Joe Miantezila Basilua, Nicolas Billard, Lucie de Gastines, Drifa Belhadi, et al.. Cardiac Adverse Events and Remdesivir in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19): A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial. Clinical Infectious Diseases, 2024, ⟨10.1093/cid/ciae170⟩. ⟨hal-04529469v2⟩
-
Nicolas Baclet, Emmanuel Forestier, Gaëtan Gavazzi, Claire Roubaud-Baudron, Vincent Hiernard, et al.. One Hundred Explicit Definitions of Potentially Inappropriate Prescriptions of Antibiotics in Hospitalized Older Patients: The Results of an Expert Consensus Study. Antibiotics, 2024, 13 (3), pp.283. ⟨10.3390/antibiotics13030283⟩. ⟨hal-04516422⟩
-
Benoit Visseaux, Jérémie Gautier, Françoise Le Boulaire, Catherine Coignard, Claire Vincent, et al.. Performance evaluation of the Access HBsAg and Access HBsAg confirmatory assays on the DxI 9000 Access immunoassay analyzer. Practical Laboratory Medicine, 2024, pp.e00390. ⟨10.1016/j.plabm.2024.e00390⟩. ⟨hal-04510055⟩
-
Cendrine Godet, Anne-Laure Brun, Francis Couturaud, François Laurent, Jean-Pierre Frat, et al.. CT Imaging Assessment of Response to Treatment in Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma. Chest, 2024, 165 (6), pp.1307-1318. ⟨10.1016/j.chest.2024.02.026⟩. ⟨hal-04473459⟩
-
Frédéric Marçon, Frédéric Lagarce, Isabelle Roland, Denis Brossard, Camille Merienne, et al.. Recommendations on training objectives and staff qualification for the manual preparation of capsules in pharmacy. Pharmaceutical Technology in Hospital Pharmacy, 2024, 9 (1), ⟨10.1515/pthp-2023-0013⟩. ⟨hal-04521923⟩
Notices
447
Dépôts
162
Liens utiles